Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This study specifically seeks to quantify the contribution of relapes to the burden of P.
vivax infections and disease by determining on the effect of radical pre-erythrocytic and
erythrocytic clearance on subsequent rates of Plasmodium spp. infection and disease in
children aged 5-10 years in a treatment to re-infection study design. In order the clear
liver-stage/blood-stages G6PD-normal children were randomised to receive Chloroquine (3 days,
standard dose) and Coartem (3 days, standard dose) plus either i) primaquine (20 days,
0.5mg/kg) or ii) placebo (20days). These drugs were administered over a period of 4 weeks.
In addition to this epidemiological data, the study will assess the natural acquisition of
cellular and humoral immune responses to P. falciparum and P. vivax, thus assisting in the
determination of correlates of clinical immunity to P. falciparum and P. vivax in PNG
children aged 5-10 years.
These data will not only be essential for development of future vaccines against P. vivax and
P falciparum but provide invaluable insight into the contribution of long-lasting
liver-stages to the force of infection with P. vivax that will contribute towards designing
more rational approaches to the treatment of P. vivax both in the context of case management
and future attempts at elimination.
Phase:
Phase 4
Details
Lead Sponsor:
Papua New Guinea Institute of Medical Research
Collaborators:
Barcelona Centre for International Health Research Swiss Tropical & Public Health Institute Walter and Eliza Hall Institute of Medical Research